Serum ras (p21) as a marker for occupationally derived lung cancer?

Clinical Chemistry and Laboratory Medicine

Volumn 38, Issue 4, 2000, Pages 301-305

  Schneider, Joachim ^a   Presek, Peter ^b   Braun, Alexandra ^b   Löffler, Simone ^b   Woitowitz, Hans Joachim ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b JUSTUS LIEBIG UNIVERSITY GIESSEN   (Germany)

Author keywords

Asbestos; Ionizing radiation; Lung cancer; Ras; Serum

Indexed keywords

ASBESTOS; CARCINOGEN; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P21; RADON; RAS PROTEIN; SEPHAROSE; TUMOR MARKER; URANIUM; VINYL CHLORIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEVICE; DISEASE PREDISPOSITION; EARLY DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MINER; MOLECULAR BIOLOGY; OCCUPATIONAL DISEASE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; STANDARD; WESTERN BLOTTING; WORKPLACE;

EID: 0033944771     PISSN: 14346621     EISSN: None     Source Type: Journal    
DOI: 10.1515/CCLM.2000.042     Document Type: Article

References (32)

1. Butz M. Beruflich verursachte Krebserkrankungen. Schriftenreihe des Hauptverbandes der gewerblichen Berufsgenossenschaften, St. Augustin, 1996.
2. Harris CC. Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991; 51:5023-44.
3. Birrer MJ, Brown PH. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res 1992; 52:2658s-64s.
4. Wynford-Thomas D. Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour. J Pathol 1991; 165:187-201.
5. Harada M, Dosaka-Akita H, Miyamoto H, Kuzumaki N, Kawakami Y. Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer. Cancer 1992; 69:72-7.
6. Niklinski J, Furman M. Clinical tumour markers in lung cancer. Eur J Cancer Prev 1995; 4:129-38.
7. Nishio H, Nakamura S, Horai T, Ikegami H, Matsuda M. Clinical and histopathologic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer. Cancer 1992; 69:1130-6.
8. Weissfeld JL, Larsen RD, Niman HL, Kuller LH. Evaluation of oncogene-related proteins in serum. Cancer Epidemiol Biomarkers Prev 1994; 3:57-62.
9. Vähäkangas KH, Samet JM, Metcalf RA, Welsh JA, Bennett WP, Lane DP, et al. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992; 339:576-80.
10. DeVuyst P. Guidelines for attribution of lung cancer to asbestos. In: Proceedings of an International Expert Meeting on Asbestos, Asbestosis and Cancer. Finnish Institute of Occupational Health (ed.), Helsinki, Finland, People and Work, Research reports. 1997; 14:92-6.
11. c-src is increased on thrombin stimulation of human platelets. Biochem J 1993; 295:41-8.
12. Schneider J, Presek P, Braun A, Bauer P, Konietzko N, Wiesner B, Woitowitz HJ. P53 protein, EGF receptor, and anti-p53 antibodies in serum from patients with occupationally derived lung cancer. Br J Cancer 1999; 80:1987-94.
13. Gazdar AF. The molecular and cellular basis of human lung cancer. Anticancer Res 1994; 13:261-8.
14. Kaye FJ, Kim YW, Otterson GA. Molecular biology of lung cancer. In: Cowell JK, editor. Molecular genetics of cancer. Oxford: BIOS Scientific Publishers, 1995:179-204.
15. Lin X, Shu W, Sun Z, Zhao J, Sun Z. A study on p21 (ras) in human lung cancer and body fluid of cancer patients. Hua-Hsi-l-Ko-Ta-Hsueh-Hsueh-Pao 1993; 24:233-6.
16. Lutz W, Sutkowski W, Krajewska B. Oncoproteins as biomarkers of preclinical form of cancer of the respiratory tract induced by environmental carcinogens. Pol J Occup Med Environ Health 1993; 6:347-55.
17. Mao L, Hruban R, Boyle JO, Tockman M, Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54:1634-7.
18. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation in human lung cancer. Cancer Res 1992; 52:2665-9.
19. Minna JD. The molecular biology of lung cancer pathogenesis. Chest 1993; 103:449-56.
20. Rusch V, Baselga J, Cordon-Cardo J, Orazem J, Zaman M, Hoda S, et al. Differential expression of the epidermal growth factor receptor and its ligands in primary non small cell lung cancers and adjacent benign lung. Cancer Res 1993; 53:2379-85.
21. Spandidos DA, Zakinthinos S, Petraki C, Sotsiou F, Yiagnisis M, Dimopoulos AM, et al. Expression of ras p21 and myc p62 oncoproteins in small cell and non small cell carcinoma of the lung. Anticancer Res 1990; 10:1105-14.
22. Anderson D, Hughes JA, Cebulska-Wasilewska A, Nizankowska E, Graca B. Ras oncoproteins in human plasma from lung cancer patients and healthy controls. Mutat Res 1996; 349:121-6.
23. Anderson D, Hughes JA, Nizankowska E, Graca B, Cebulska-Wasilewska A, Wierzewska A, et al. Factors affecting various biomarkers in untreated lung cancer patients and healthy donors. Environ Mol Mutagen 1997; 30:205-16.
24. Anderson D, Hughes JA, Cebulska-Wasilewska A, Nizankowska E, Graca B. Ras p21 protein levels in human plasma from patients with chronic obstructive pulmonary disease (COPD) compared with lung cancer patients and healthy controls. Mutat Res 1998; 403:229-35.
25. Brandt-Rauf PW, Niman HL. Serum screening for oncogene proteins in workers exposed to PCBs. Br J Ind Med 1988; 45:689-93.
26. Brandt-Rauf PW, Smith S, Niman HL, Goldstein MD, Favata E. Serum oncogene proteins in hazardous-waste workers. J Soc Occup Med 1989; 39:141-3.
27. Brandt-Rauf PW. Advances in cancer biomarkers as applied to chemical exposures: the ras oncogene and p21 protein and pulmonary carcinogenesis. J Occup Med 1991; 33:951-5.
28. Brandt-Rauf PW, Smith S, Hemminki K, Koskinen H, Vainio H, Niman H, et al. Serum oncoproteins and growth factors in asbestosis and silicosis patients. Int J Cancer 1992; 50:881-5.
29. Shalitin C, Epelbaum R, Moskovitz B, Segal R, Valansi C, Werner M, et al. Increased levels of a 21-kDa protein in the circulation of tumor-bearing patients. Cancer Detect Prev 1994; 18:357-65.
30. Husgafvel-Pursiainen K, Hackman P, Ridanpää M, Anttila S, Karajalainen A, Partanen T, et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 1993; 53:250-6.
31. Brandt-Rauf PW, The c-erbB transmembrane growth factor receptors as serum biomarkers in human cancer studies. Mutation Res 1995; 333:203-8.
32. Kakkanas A, Spandidos DA. Ras p21 onco-protein in the sera of mice carrying an experimentally induced tumor and in human cancer patients. In Vivo 1990; 4:115-20.